Literature DB >> 12559123

Modification of the philanthotoxin-343 polyamine moiety results in different structure-activity profiles at muscle nicotinic ACh, NMDA and AMPA receptors.

I R Mellor1, T J Brier, F Pluteanu, K Strømgaard, A Saghyan, N Eldursi, M J Brierley, K Andersen, J W Jaroszewski, P Krogsgaard-Larsen, P N R Usherwood.   

Abstract

Voltage-dependent, non-competitive inhibition by philanthotoxin-343 (PhTX-343) analogues, with reduced charge or length, of nicotinic acetylcholine receptors (nAChR) of TE671 cells and ionotropic glutamate receptors (N-methyl-D-aspartate receptors (NMDAR) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR)) expressed in Xenopus oocytes from rat brain RNA was investigated. At nAChR, analogues with single amine-to-methylene or amine-to-ether substitutions had similar potencies to PhTX-343 (IC(50)=16.6 microM at -100 mV) whereas PhTX-(12), in which both secondary amino groups of PhTX-343 were replaced by methylenes, was more potent than PhTX-343 (IC(50)=0.93 microM at -100 mV). Truncated analogues of PhTX-343 were less potent. Inhibition by all analogues was voltage-dependent. PhTX-343 (IC(50)=2.01 microM at -80 mV) was the most potent inhibitor of NMDAR. At AMPAR, most analogues were equipotent with PhTX-343 (IC(50)=0.46 microM at -80 mV), apart from PhTX-83, which was more potent (IC(50)=0.032 microM at -80 mV), and PhTX-(12) and 4,9-dioxa-PhTX-(12), which were less potent (IC(50)s>300 microM at -80 mV). These studies show that PhTX-(12) is a selective nAChR inhibitor and PhTX-83 is a selective AMPAR antagonist.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559123     DOI: 10.1016/s0028-3908(02)00336-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

Review 1.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

3.  Modeling noncompetitive antagonism of a nicotinic acetylcholine receptor.

Authors:  Denis B Tikhonov; Ian R Mellor; Peter N R Usherwood
Journal:  Biophys J       Date:  2004-07       Impact factor: 4.033

4.  Open-channel blockade is less effective on GluN3B than GluN3A subunit-containing NMDA receptors.

Authors:  David W McClymont; John Harris; Ian R Mellor
Journal:  Eur J Pharmacol       Date:  2012-04-27       Impact factor: 4.432

5.  Block of nicotinic acetylcholine receptors by philanthotoxins is strongly dependent on their subunit composition.

Authors:  Hamid S Kachel; Rohit N Patel; Henrik Franzyk; Ian R Mellor
Journal:  Sci Rep       Date:  2016-11-30       Impact factor: 4.379

6.  Neuroprotection Against NMDA-Induced Retinal Damage by Philanthotoxin-343 Involves Reduced Nitrosative Stress.

Authors:  Mohamad Haiqal Nizar Mohamad; Izuddin Fahmy Abu; Muhammad Fattah Fazel; Renu Agarwal; Igor Iezhitsa; Norsham Juliana; Ian R Mellor; Henrik Franzyk
Journal:  Front Pharmacol       Date:  2021-12-14       Impact factor: 5.810

7.  The Effects of Structural Alterations in the Polyamine and Amino Acid Moieties of Philanthotoxins on Nicotinic Acetylcholine Receptor Inhibition in the Locust, Schistocerca gregaria.

Authors:  Victoria L Luck; David P Richards; Ashif Y Shaikh; Henrik Franzyk; Ian R Mellor
Journal:  Molecules       Date:  2021-11-19       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.